Table 3.
Associations of SNPs with prostate cancer risk stratified by serum antioxidants in PCPT placebo arm.
| Gene | SNP | Genotype | Ca/Co a | OR (95%CI)b,c | pd,e | Ca/Co a | OR (95%CI)b,c | pd,e | P-inter f |
|---|---|---|---|---|---|---|---|---|---|
| Lycopene | Low-level (<0.38 µg/mL) | High-level (≥0.38 µg/mL) | |||||||
| APEX1 | rs1760944 | GG | 167/166 | 1.00 | 0.08 | 137/171 | 1.00 | 0.006 | 0.002 |
| TG | 220/252 | 0.83 (0.62-1.11) | 200/198 | 1.29 (0.94-1.76) | |||||
| TT | 64/87 | 0.72 (0.48-1.07) | 0.12 | 81/60 | 1.80 (1.18-2.75) | ||||
| NQO1 | rs1800566 | CC | 300/337 | 1.00 | 0.45 | 285/245 | 1.00 | 0.04 | 0.04 |
| CT | 123/157 | 0.95 (0.71-1.27) | 113/153 | 0.69 (0.50-0.94) | |||||
| TT | 26/19 | 1.65 (0.88-3.10) | 21/28 | 0.78 (0.41-1.46) | |||||
| β-cryptoxanthin | Low-level (<0.10 µg/mL) | High-level (≥0.10 µg/mL) | |||||||
| ERCC4 | rs1800067 | GG | 325/417 | 1.00 | 0.66 | 237/224 | 1.00 | 0.01 | 0.02 |
| AG | 47/52 | 1.10 (0.71-1.70) | 27/52 | 0.48 (0.29-0.81) | |||||
| AA | 2/2 | 1.08 (0.14-8.22) | 2/2 | 0.71 (0.10-5.23) | |||||
| AG/AA | 49/54 | 1.10 (0.72-1.69) | 0.66 | 29/54 | 0.49 (0.30-0.82) | 0.006 | 0.01 | ||
a
Ca/Co, Cases and Controls.
b
OR, odds ratio; 95%CI, 95% confidence interval.
c
Adjusted for baseline age, race, education, body mass index, family history of prostate cancer, diabetes status, smoking status, physical activity, and alcohol consumption.
d
P-trend for genetic dose response determined by coding genotypes as having 0, 1, or 2 variant allele, which was subsequently analyzed as an ordinal variable.
e
P for heterogeneity from dominant or recessive models.
f
P for interaction between genotype (ordinal variable)-serum level of antioxidants (low vs. high) using the likelihood ratio test.